$1.10+0.02 (+1.38%)
News25/Ratings1
Price$1.10-0.25 (-18.52%)
2026-01-212026-04-24
News · 26 weeks39-92%
2025-11-022026-04-26
Mix2190d
- Insider7(33%)
- SEC Filings7(33%)
- Other4(19%)
- Leadership2(10%)
- Earnings1(5%)
Latest news
25 items- PRAEON Biopharma Sets Annual Shareholder Meeting- Annual Shareholder Meeting to be held at 10:00 am PT on June 17, 2026 - IRVINE, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced that its Annual Shareholder Meeting will be held at 10:00 am Pacific Time (PT) on Wednesday, June 17, 2026 and will be held in the Company's offices at 5 Park Plaza, Suite 1750, Irvine, CA 92614. Meeting materials are expected to be made available to shareholders on or about April 29, 2026. NYSE Required Disclosure Regarding Audit Opinion
- INSIDERSEC Form 4 filed by Bencich John4 - AEON Biopharma, Inc. (0001837607) (Issuer)
- INSIDERSEC Form 3 filed by new insider Bencich John3 - AEON Biopharma, Inc. (0001837607) (Issuer)
- PRAEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced that, on April 2, 2026, in connection with the appointment of John Bencich as Chief Financial Officer, the Company's Compensation Committee of the Board of Directors (the "Compensation Committee") approved the grant of inducement awards. The Compensation Committee approved the grant to Mr. Bencich of 754,717 restricted stock units ("RSUs") under AEON's 2025 Employment Inducement Incentive Award Plan (the "Induce
- SECAEON Biopharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - AEON Biopharma, Inc. (0001837607) (Filer)
- PRAEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing StandardsIRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced that on March 31, 2026, it received a notice (the "Notice") from NYSE American LLC ("NYSE American") indicating that, following its year-end financial results, the Company is not in compliance with an additional continued listing standard set forth in the NYSE American Company Guide (the "Company Guide"). As previously disclosed, on February 3, 2025, the Company received a notice (the "Original Notice") that it
- SECSEC Form 10-K filed by AEON Biopharma Inc.10-K - AEON Biopharma, Inc. (0001837607) (Filer)
- SECAEON Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AEON Biopharma, Inc. (0001837607) (Filer)
- PRAEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program– Announced positive initial comparative analytical results, confirming identical amino-acid sequencing and highly similar functional characteristics to BOTOX® – – Reported positive FDA BPD Type 2a meeting, with FDA feedback providing a clear framework for advancing the comparative analytical plan for ABP-450 biosimilar program – – Strengthened balance sheet through $6 million PIPE financing and Daewoong note exchange, reducing outstanding debt by more than 90% – – Appointed John Bencich as Chief Financial Officer, adding significant capital markets and strategic leadership experience – IRVINE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (
- PRAEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar ProgramFDA provided constructive feedback on Company's analytical similarity strategy under the 351(k) biosimilar pathway Company continues to execute its analytical program and plans to request a BPD Type 2b meeting with the FDA in 2026 to discuss next steps in the development of ABP-450 as a biosimilar to BOTOX® IRVINE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced feedback from the U.S. Food and Drug Administration ("FDA" or the "Agency") following a successful Bios
- INSIDERCHIEF MEDICAL OFFICER Oh Chad was granted 2,179,372 shares, increasing direct ownership by 53,626% to 2,183,436 units (SEC Form 4)4 - AEON Biopharma, Inc. (0001837607) (Issuer)
- SECAEON Biopharma Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - AEON Biopharma, Inc. (0001837607) (Filer)
- PRAEON Biopharma Appoints John Bencich as Chief Financial OfficerIRVINE, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve accelerated and full-label U.S. market entry, today announced the appointment of John Bencich as Chief Financial Officer. Mr. Bencich joins AEON at a pivotal stage in the Company's evolution as it prepares to execute through its next phase of critical regulatory milestones. "John's appointment represents an important step forward for AEON as we enter a period of accelerated execution," said Rob Bancroft, President and Chief Executive Officer of AEON. "His d
- INSIDERCLO, CSO, and Corp Secretary Wilson Alexander Blair was granted 2,179,372 shares, increasing direct ownership by 59,988% to 2,183,005 units (SEC Form 4)4 - AEON Biopharma, Inc. (0001837607) (Issuer)
- INSIDERPRINCIPAL ACCOUNTING OFFICER Sy Jennifer was granted 1,500,925 shares, increasing direct ownership by 597,978% to 1,501,176 units (SEC Form 4)4 - AEON Biopharma, Inc. (0001837607) (Issuer)
- PRAEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual MeetingIRVINE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve accelerated and full-label U.S. market entry, today announced a poster presentation at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026, in Chicago, IL. The abstract builds upon analytical data previously reported by the Company demonstrating identical primary amino acid sequence between ABP-450 and the reference product, based on 93.5%–99.3% peptide sequence coverage across BoNT/A1 and associated accessory protein
- INSIDERPRESIDENT & CEO Bancroft Robert E. was granted 3,000,000 shares, increasing direct ownership by 1,694% to 3,177,103 units (SEC Form 4)4 - AEON Biopharma, Inc. (0001837607) (Issuer)
- SECSEC Form 424B3 filed by AEON Biopharma Inc.424B3 - AEON Biopharma, Inc. (0001837607) (Filer)
- SECSEC Form EFFECT filed by AEON Biopharma Inc.EFFECT - AEON Biopharma, Inc. (0001837607) (Filer)
- SECSEC Form S-3 filed by AEON Biopharma Inc.S-3 - AEON Biopharma, Inc. (0001837607) (Filer)
- INSIDERNew insider Daewoong Co., Ltd claimed ownership of 12,009,737 shares (SEC Form 3)3 - AEON Biopharma, Inc. (0001837607) (Issuer)
- SECAEON Biopharma Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Leadership Update, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits8-K - AEON Biopharma, Inc. (0001837607) (Filer)
- PRAEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions- AEON confirmed that earlier today it held its BPD Type 2a Meeting with the FDA, in line with prior guidance, and is now awaiting official meeting minutes - - Separately, AEON shareholders today voted in favor of the proposals required to complete the transactions announced in November, including the consummation of the PIPE financing and the related Daewoong note exchange - IRVINE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA), today reported on two separate posi
- SECAEON Biopharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - AEON Biopharma, Inc. (0001837607) (Filer)
- SECSEC Form DEF 14A filed by AEON Biopharma Inc.DEF 14A - AEON Biopharma, Inc. (0001837607) (Filer)